Connect with us

Press Release

Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery

Published

on

–News Direct–

By Meg Flippin, Benzinga

IceCure Medical Ltd. (NASDAQ: ICCM), which is set to submit results from the largest cryoablation study of its kind to the FDA, may set a new standard of care for early-stage breast cancer in women who elect not to have surgery. This could be a game-changer for the medical community and IceCure alike.

When it comes to the early onset of breast cancer, the typical treatment protocol is for women to undergo a lumpectomy followed by chemotherapy, hormone or radiation therapy. The lumpectomy involves removing the tumor and some healthy tissue around it surgically in a hospital operating room. It requires heavy sedation, is often painful and has a long recovery time.

While tens of thousands of lumpectomies are performed annually in the U.S., it is not a perfect solution. In about 20% of cases, a second surgical procedure known as a re-excision is required to get rid of lingering cancer cells. Some tumors are difficult to spot or feel which makes them hard to locate during the surgery and thus follow-up surgeries are often required. Re-excision can not only be costly, it adds to the recovery time and weighs on the patients mental health. Some women, concerned about their future, opt at that point for a mastectomy.

Freezing Tumors May Be The Answer

With about 280,000 women diagnosed with invasive breast cancer each year, and around 340,000 total cases, finding better alternatives is front and center for many healthcare providers, drug companies and biotechs including IceCure Medical Ltd. (NASDAQ: ICCM). IceCure is expanding the use of ProSense, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.

Cryoablation is a potentially attractive option for treating tumors because it is minimally invasive and has little pain associated with it. Tumors can be seen clearly by using imaging modalities like ultrasound or computerized tomography (CT), accurately destroying diseased tissue within the tumor zone. Cryoablation reduces surgery-related complications, downtime for the patient and economic burden to the insurer and the medical provider, as well as reducing the need for secondary lumpectomy in breast cancer.

IceCure likens its ProSense procedure for breast tumors to that of going to the dentist, with no scarring or general anesthesia required. Rather, IceCure relies on lidocaine used locally so there is no need to go to a hospital or stay overnight to recover, all of which reduces costs and speeds up recovery.

Unlike lumpectomies, cryoablation does not involve the excision of breast tissue, thereby eliminating many of the adverse cosmetic effects of tumor excision as well. Some researchers have even called cryoablation the ultimate esthetic solution for breast cancer because it reduces the need for pre-emptive or corrective surgical procedures to maintain or restore breast volume, contour and symmetry. For all of those reasons, breast cancer cryoablation has emerged as a possible alternative to lumpectomy for early-stage breast cancer over the past decade.

Promising Topline Results

IceCure recently announced positive topline results from its ICE3 study, which it says is the largest controlled multicenter clinical trial ever performed in the U.S. for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors, following the five-year follow-up evaluation of the ICE3 study's last patient.

In the ICE3 study, 96.39% of patients (187 out of 194 patients) were local recurrence-free with no significant device-related adverse events or complications reported. Based on those topline results, the company said ProSense has the potential to be a safe and effective alternative to lumpectomy for early-stage breast cancer.

The company says it is on track to submit the full data set and results to the U.S. Food and Drug Administration (FDA) for marketing clearance any day now, and Prosense is already approved for breast cancer in other territories like Europe. The breast cancer market size is significant, and was valued at $31.89 billion in 2022 and is forecast to hit $70.53 billion by 2030, growing at a CAGR of 10.43% over 2023-2030. The tumor ablation market is expected to reach $2.4 billion by 2028, growing at a CAGR of 13.2% from now until then.

"We are very pleased with this topline outcome and believe these results demonstrate a highly favorable safety and efficacy profile that positions ProSense as a desirable alternative to lumpectomy for early-stage breast cancer," said Eyal Shamir, Chief Executive Officer of IceCure.

"While the FDA evaluates the data, we are optimistic its upcoming decision will give women in the U.S. the same access as those who are already benefiting from ProSense in other countries, he said. ProSense has regulatory approval in 15 countries for a broad range of indications including in Europe, Brazil, Canada and China.

Incidents of breast cancer are increasing around the world, with many people facing invasive and time-consuming procedures. While lumpectomies will continue to be necessary sometimes, companies like IceCure may be giving patients an alternative way to fight this disease. With full data being submitted to the FDA any day now, if approved it could prove to be game-changing for IceCure and women across America diagnosed with early-stage breast cancer.

Featured photo by National Cancer Institute on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/game-changing-tumor-freezing-technology-has-the-potential-to-offer-women-first-ever-minimally-invasive-alternative-to-breast-lumpectomy-surgery-883457450

Benzinga

comtex tracking

COMTEX_450755015/2655/2024-04-12T13:35:15

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

FishWar Officially Powered by Sei: Elevating the GameFi Experience

Published

on

New York, NY – 21/10/2024 – (SeaPRwire) – FishWar, an innovative Web3 gaming platform that has captivated over a million players worldwide, is proud to announce its official integration with Sei the first parallelized EVM blockchain. This marks a significant milestone in FishWar’s journey to revolutionize the GameFi space by enhancing gameplay, scalability, and overall user experience.

Sei, renowned for its lightning-fast execution and scalability, brings the combined advantages of Ethereum and Solana to FishWar. As the fastest parallel blockchain, Sei enhances FishWar’s infrastructure, delivering faster transactions, lower fees, and a seamless gaming experience for its ever-growing community.

Key Benefits of the Integration:

  1. Enhanced Performance: With Sei’s parallelized EVM, FishWar players will experience faster, more efficient transactions, ensuring smooth gameplay during PVP tournaments, PVE battles, and in-game purchases.
  2. Scalable Infrastructure: Sei’s ability to process up to 12,500 transactions per second means FishWar is well-equipped to handle its growing user base, which now exceeds 1 million players.
  3. Lower Fees: Sei keeps transaction costs minimal, allowing players to fully immerse in FishWar without the concern of high fees, making the game accessible to all.

This integration bolsters FishWar’s commitment to providing an immersive Web3 gaming experience where players build armies, compete in strategic battles, and earn valuable $FISHW tokens. With Sei’s robust blockchain technology, FishWar is poised to deliver an even faster, smoother, and more thrilling adventure in its post-apocalyptic ocean world.

“We are thrilled to officially power FishWar with Sei. This integration allows us to offer faster, more reliable gameplay to our users while leveraging Sei’s advanced blockchain technology. With this, FishWar is well-positioned to lead the next generation of Web3 gaming,” said Alan Wang, CEO of FishWar.

About Sei

Sei is a Layer 1 that combines the advantages of Ethereum and Solana: the dominant development standard of Ethereum with the performance of Solana. The V2 update for Sei makes it the first parallelized EVM. Serving as a new scaling approach for the Ethereum ecosystem while achieving even faster speeds than Solana. Sei launched its mainnet in 2022 and has a growing ecosystem with key teams from Ethereum, Solana, Polygon, Arbitrum, and others deploying. The team is backed by Multicoin, Jump, Coinbase Ventures, and many more.

Website | X (Former Twitter) | Discord | Telegram

About FishWar

FishWar is an innovative Web3 game set in a post-apocalyptic ocean, where players dive into intense battles, strategic gameplay, and real-time PVP tournaments. FishWar merges the thrilling world of GameFi with the evolving realms of Web3, offering an immersive gaming experience for players to earn rewards while building their armies.

Website | X (Former Twitter) | Discord | Telegram

Media contact

Brand: FishWar

Contact: Media team

Email: support@fishwar.io

Website: https://fishwar.io

 

The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith.

Sectors: Top Story, Corporate News

SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Eminence Capital Accelerates Expansion in the Asia-Pacific Market

Published

on

Eminence Capital LTD., a subsidiary of Mesirow, specializes in investment management, capital markets, and investment banking in the Asia-Pacific region. It also offers advisory services, including retirement planning and wealth management. Its core business includes a wide range of traditional and alternative investment strategies, utilizing advanced trading technologies and comprehensive investment analysis tools to help clients achieve higher returns with lower risk in global markets. Eminence Capital’s goal is to provide convenient investment channels for global clients, especially as the Asia-Pacific region becomes a focal point for international investors.

IMG_257

Mesirow, a privately held financial services firm headquartered in Chicago, Illinois, is employee-owned, with 100% of its voting shares held by employees. Mesirow provides services in investment management, capital markets, wealth management, and investment banking. Founded in 1937, Mesirow has established a strong reputation in the financial industry and operates offices in 21 cities worldwide.

Mesirow’s investment banking division offers sell-side advisory, corporate divestitures, buy-side advisory, private placements, debt advisory, and capital restructuring services. The company focuses on serving institutional investors, public sector entities, and broker-dealers. Its private equity division has invested in private equity markets on behalf of various institutional and high-net-worth clients. Mesirow is committed to global growth, carefully monitoring global financial market dynamics, expanding its international outlook, and actively seeking opportunities in emerging markets. The firm is dedicated to building core competencies in financial markets and providing informed decision-making support to global investors.

As a subsidiary of Mesirow, Eminence Capital LTD. will take full responsibility for strategic direction in the Asia-Pacific region. It has successfully completed the filing process with the U.S. Securities and Exchange Commission (SEC), obtaining an exemption from securities sales regulations. This compliance certificate ensures that the company can operate within a flexible capital market framework, allowing it to quickly respond to market opportunities while maintaining adherence to financial regulations, thereby enhancing its competitiveness in global capital markets.

In recent years, the Asia-Pacific region has garnered global attention due to its economic vitality and technological innovation, attracting increasing international capital. Eminence Capital recognizes this potential and is committed to providing a bridge for global investors to access the Asia-Pacific capital markets. With a deep understanding of the region’s complexities and opportunities, Eminence Capital offers tailored financial solutions through localized operations, making it an ideal partner for both local and international investors.

Through Eminence Capital, Mesirow’s entry into the Asia-Pacific market supports its broader global expansion strategy, enabling clients to achieve global asset allocation and portfolio diversification. This strategy not only brings greater global investment opportunities to the Asia-Pacific market but also provides global investors access to this rapidly growing region. Eminence Capital delivers competitive services and solutions to both individual and institutional investors.

Eminence Capital’s advanced trading system allows clients to swiftly adapt to global market changes, improving transaction speed and efficiency. The system enables clients to benefit from significant price advantages and flexibly adjust their investment strategies with 24/7 support. Additionally, Eminence Capital offers a free customer relationship management (CRM) system and a suite of investment analysis tools, making portfolio management and transaction reporting more convenient and efficient.

Moreover, Eminence Capital’s platform not only focuses on expanding investment opportunities but also aims to optimize trade execution and reduce investment costs. Its technology platform allows institutional investors to access global markets at highly competitive costs while benefiting from efficient and transparent settlement services. This makes Eminence Capital a top choice for global investors, particularly in the fast-growing Asia-Pacific market.

Through Eminence Capital’s global expansion and localized operations, Mesirow has strengthened its ties with global capital markets, further reinforcing its leadership in the financial services industry. This strategic partnership will drive Mesirow’s and its subsidiaries’ growth in global markets, laying a solid foundation for continued success in the future.

Eminence Capital LTD.’s innovative trading platform and financial services offer significant convenience to investors, serving as an important gateway to global capital markets. As the Asia-Pacific market continues to mature, Eminence Capital will maintain its pivotal role in the region, combining global and localized strategies to offer professional and efficient financial services to both global and regional investors.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

New Action-Packed Thriller “Christmas in Havana” Explores Love and Loyalties Amidst International Intrigue

Published

on

Centreville, VA – Christmas in Havana, the gripping third installment of Stephen Hiemstra’s Masquerade series, is now available. Combining political intrigue, action, and romance, Hiemstra’s latest novel dives deep into the complexities of love and loyalty in the face of personal grief and international crisis.

Luke Stevens, a CIA agent working undercover as a pastor, finds himself haunted by his ex-wife’s death as he eulogizes her. Just when Luke is ready to move forward, North Korean law student Ruth Chǔ (Yong Dae Chû) enters his life. She is secretly entangled in a dangerous game of espionage, working as a courier for North Korea’s Reconnaissance General Bureau (RGB) to support her family. Both Luke and Ruth must navigate their complicated pasts and present loyalties, all while international tensions threaten to boil over.

When China’s plan to invade Taiwan comes to light, with Cuba playing a key role in the diversionary attacks, Luke and Ruth are thrown into a whirlwind of danger. The novel raises the stakes with rogue operatives, international betrayal, and a contract placed on Luke’s life. Despite the chaos surrounding them, Luke and Ruth form a bond, quietly supporting each other as they face impossible choices.

Hiemstra’s skillful writing combines fast-paced action with thoughtful character development. Readers are treated to rapid-fire dialogue and a suspenseful plot that turns on a dime, keeping them on the edge of their seats. As Luke and Ruth struggle with their own personal dilemmas, Hiemstra skillfully weaves in commentary on international politics, hinting at larger global consequences and political missteps.

Praise for Christmas in Havana

“Having traveled to Havana, I can attest to the city’s rich history and intrigue, and Stephen Hiemstra captures this perfectly. Christmas in Havana is a thrilling read filled with action and suspense.”

— Percy M. Burns, Author of Glorious Freedom

“Stephen Hiemstra guides readers through a captivating adventure that reflects life itself, blending action and emotion with ease. Christmas in Havana is a fascinating story of love, loyalty, and survival.”

— Julio Martinez, Senior Pastor, Shadai Phoenix Church

“Christmas in Havana is a powerful conclusion to Hiemstra’s trilogy. It’s a fast-moving drama full of romance, action, and spiritual reflection.”

— Sharron Giambanco, Business Owner and Writer

About the Author

Stephen W. Hiemstra (MDiv, PhD) is a husband, father, and writer with a passion for Christian spirituality and ministry. After a 27-year career as an economist with the U.S. government, Hiemstra transitioned into ministry, serving as a pastor and writer. He has published numerous books, including Called Along the Way and A Christian Guide to Spirituality, and writes regularly on his blog. Stephen holds a Master of Divinity from Gordon-Conwell Theological Seminary and a PhD in Agricultural Economics from Michigan State University.

For more information and to sign up for Stephen’s newsletter,

Visit www.stephenwhiemstra.net

Contact Information:

Contact Person : Stephen W. Hiemstra

Email: t2pneuma@gmail.com

Blog: https://t2pneuma.net

Books: https://t2pneuma.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST